Lactulose

/Tag:Lactulose

Abstract Number: 395

RIFAXIMIN AND LACTULOSE COMBINATION THERAPY VERSUS LACTULOSE ALONE FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: A POOLED ANALYSIS OF TWO RANDOMIZED TRIALS

Background: Rifaximin 550 mg tablets is a nonsystemic antibiotic indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence in adults and may be used in combination with lactulose. Practice guidelines state that rifaximin [...]

By | 2019-03-11T14:25:21-04:00 March 11th, 2019|Hospital Medicine 2019, Research, Transitions of Care|Comments Off on RIFAXIMIN AND LACTULOSE COMBINATION THERAPY VERSUS LACTULOSE ALONE FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: A POOLED ANALYSIS OF TWO RANDOMIZED TRIALS

Abstract Number: 228

RIFAXIMIN ALONE VERSUS RIFAXIMIN AND LACTULOSE COMBINATION THERAPY FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: SAFETY PROFILE IN PATIENTS WITH CIRRHOSIS

Background: Rifaximin 550 mg tablets is a nonsystemic antibiotic indicated for reducing the risk of overt hepatic encephalopathy (OHE) recurrence in adults and may be used alone or in combination with the cathartic lactulose. This [...]

By | 2019-03-11T14:21:17-04:00 March 11th, 2019|Hospital Medicine 2019, Patient Safety, Research|Comments Off on RIFAXIMIN ALONE VERSUS RIFAXIMIN AND LACTULOSE COMBINATION THERAPY FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: SAFETY PROFILE IN PATIENTS WITH CIRRHOSIS

HM2018 Abstract Number: 567

A CASE OF RECURRENT HEPATIC ENCEPHALOPATHY: LACTULOSE IS NOT THE ANSWER

Case Presentation: A 51-year-old woman presented with recurrent confusion and altered mental status over the past 6 months. She reported associated hallucinations, altered sleep cycle and hyper-arousal symptoms. She was treated with lactulose and rifaximin [...]

By | 2018-03-19T15:44:08-04:00 March 19th, 2018|Adult, Clinical Vignettes, Uncategorized|Comments Off on A CASE OF RECURRENT HEPATIC ENCEPHALOPATHY: LACTULOSE IS NOT THE ANSWER